Moreover, HDAC inhibition, in combination with PARP inhibition, elicited a robust tumor‐intrinsic innate immune response characterized by increased infiltration of T cells and dendritic cells (DCs) within the tumor microenvironment, ultimately enhancing the efficacy of ICB therapy. This evidence concerns the gene HDAC9 and neoplasm.